Search

Your search keyword '"Manal F, Ismail"' showing total 4 results
Start Over Author "Manal F, Ismail" Language english
4 results on '"Manal F, Ismail"'

1. Mutational analysis of the PTPN11 gene in Egyptian patients with Noonan syndrome

Author

Mona L. Essawi, Manal F. Ismail, Hanan H. Afifi, Maha M. Kobesiy, Ahmed El Kotoury, and Maged M. Barakat

Subjects
Egyptian patients, mutational analysis, Noonan syndrome, PTPN11, SHP-2, Medicine (General), R5-920
Abstract

Noonan syndrome (NS) is inherited as an autosomal dominant disorder with dysmorphic facies, short stature, and cardiac defects, which can be caused by missense mutations in the protein tyrosine phosphatase nonreceptor type 11 (PTPN11) gene, which encodes src homology region 2 domain containing tyrosine phosphatase-2 (SHP-2), a protein tyrosine phosphatase that acts in signal transduction downstream to growth factors and cytokines. The current study aimed to study the molecular characterization of the PTPN11 gene among Egyptian patients with Noonan syndrome. Methods: Eleven exons of the PTPN11 gene were amplified and screened by single stranded conformational polymorphism (SSCP). DNA samples showing band shift in SSCP were subjected to sequencing. Results: Mutational analysis of the PTPN11 gene revealed T→C transition at position 854 in exon 8, predicting Phe285Ser substitution within PTP domain of SHP-2 protein, in one NS patient and –21C→T polymorphism in intron 7 in four other cases. Conclusion: Knowing that NS is phenotypically heterogeneous, molecular characterization of the PTPN11 gene should serve to establish NS diagnosis in patients with atypical features, although lack of a mutation does not exclude the possibility of NS.

Published
2013
Full Text
View/download PDF

2. MicroRNAs 9 and 370 Association with Biochemical Markers in T2D and CAD Complication of T2D.

Author

Tarek M Motawae, Manal F Ismail, Marwa I Shabayek, and Mae M Seleem

Subjects
Medicine, Science
Abstract

MicroRNAs (miRNAs) are small non coding RNAs with essential roles, of which any alteration leads to several conditions. Their roles in diabetes (DM) and its vascular complications have not been completely assessed.to study the association of two miRNAs; 9 and 370, with biochemical parameters of type 2 diabetic (T2D), dyslipidemia and coronary artery disease (CAD).Blood samples were taken from 200 subjects of both genders, in the Outpatient clinic of Al Qasr El-Einy teaching hospitals, in which levels of both miRNAs (using real time PCR) and routine parameters were measured. Subjects were divided over four groups, 50 in each group as follows; patients with T2D, patients with CAD, patients with T2D and CAD, and healthy control subjects.miRNA 9 levels were expected to be over expressed in diabetic patients, while miRNA 370 levels were expected to be over expressed in those suffering from CAD and their association with CAD complication of T2D.miRNA 9 levels were significantly higher in T2D patients and T2D patients with CAD, (1.18±0.07, and 1.31±0.08 respectively), while miRNA 370 levels were significantly higher in T2D patients, CAD patients, and T2D patients with CAD (0.59±0.05, 1.00±0.05, and 1.20±0.06 respectively), compared to control group at p = 0.000. In addition both miRNAs were still significantly associated with each other even after conducting multiple regression analysis.This study associates the possible role of miRNAs in the diagnosis/prognosis of CAD complication of T2D.

Published
2015
Full Text
View/download PDF

3. Peroxisome Proliferator-Activated Receptor Gamma in Obesity and Colorectal Cancer: the Role of Epigenetics

Author

Noha H Sayed, Olfat G. Shaker, Manal F. Ismail, and Tarek K. Motawi

Subjects
0301 basic medicine, medicine.medical_specialty, Colorectal cancer, Peroxisome proliferator-activated receptor, lcsh:Medicine, Article, Epigenesis, Genetic, 03 medical and health sciences, 0302 clinical medicine, Downregulation and upregulation, Internal medicine, microRNA, medicine, Humans, Epigenetics, Circulating MicroRNA, Obesity, Receptor, Promoter Regions, Genetic, lcsh:Science, chemistry.chemical_classification, Regulation of gene expression, Multidisciplinary, business.industry, lcsh:R, DNA Methylation, medicine.disease, PPAR gamma, MicroRNAs, 030104 developmental biology, Endocrinology, chemistry, Gene Expression Regulation, 030220 oncology & carcinogenesis, Case-Control Studies, DNA methylation, lcsh:Q, business, Colorectal Neoplasms
Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that is deregulated in obesity. PPARγ exerts diverse antineoplastic effects. Attempting to determine the clinical relevance of the epigenetic mechanisms controlling the expression PPARγ and susceptibility to colorectal cancer (CRC) in obese subjects, this study investigated the role of some microRNAs and DNA methylation on the deregulation of PPARγ. Seventy CRC patients (34 obese and 36 lean), 22 obese and 24 lean healthy controls were included. MicroRNA levels were measured in serum. PPARγ promoter methylation was evaluated in peripheral blood mononuclear cells (PBMC). PPARγ level was evaluated by measuring mRNA level in PBMC and protein level in serum. The tested microRNAs (miR-27b, 130b and 138) were significantly upregulated in obese and CRC patients. Obese and CRC patients had significantly low levels of PPARγ. A significant negative correlation was found between PPARγ levels and the studied microRNAs. There was a significant PPARγ promoter hypermethylation in CRC patients that correlated to low PPARγ levels. Our results suggest that upregulation of microRNAs 27b, 130b and 138 is associated with susceptibility to CRC in obese subjects through PPARγ downregulation. Hypermethylation of PPARγ gene promoter is associated with CRC through suppression of PPARγ regardless of BMI.

Published
2017
Full Text
View/download PDF

4. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: Prognostic and predictive markers in triple-negative and non-triple-negative breast cancer

Author

Abeer M. Ashmawy, Abdel-Rahman N. Zekri, Sabry Shaarawy, Marwa Mohanad, Abeer Bahhnassy, Manal F. Ismail, and Ahmed El-Bastawisy

Subjects
Adult, Vascular Endothelial Growth Factor A, Cancer Research, medicine.medical_treatment, Triple Negative Breast Neoplasms, Biology, Biochemistry, Disease-Free Survival, Targeted therapy, Metastasis, Receptor, IGF Type 1, Transforming Growth Factor beta1, Insulin-like growth factor, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Biomarkers, Tumor, Humans, Insulin-Like Growth Factor I, Neoplasm Metastasis, Molecular Biology, Survival rate, Cyclophosphamide, Triple-negative breast cancer, Aged, Epirubicin, vascular endothelial growth factor, Cancer, triple-negative breast cancer, transforming growth factor-β, insulin growth factor/insulin growth factor receptor I, Articles, Middle Aged, medicine.disease, Prognosis, Gene Expression Regulation, Neoplastic, Vascular endothelial growth factor A, Treatment Outcome, Oncology, Cancer research, Molecular Medicine, Female, Fluorouracil, Transforming growth factor
Abstract

In the current study, the prognostic and predictive values of serum transforming growth factor-β1 (TGF-β1), insulin-like growth factor I (IGF-I)/IGF-I receptor (IGF-IR) and vascular endothelial growth factor-A (VEGF-A) were evaluated in triple-negative and non-triple-negative breast cancer (TNBC and non-TNBC). The aim was to identify a group of serological biomarkers and to identify possible candidates for targeted therapy in patients with TNBC and non-TNBC. Protein levels of TGF-β1, IGF-I/IGF-IR and VEGF-A in the serum were measured in 43 TNBC, 53 non-TNBC and 20 normal control participants using quantitative ELISA assays. Results were correlated against standard prognostic factors, response to treatment and survival. TNBC was identified to be associated with poor prognosis and serum levels of VEGF-A and IGF/IGF-IR were significantly higher in the TNBC group compared with the non-TNBC group. IGF-IR and VEGF-A overexpression was observed to be correlated with TGF-β1 expression and all of the markers investigated were associated with metastasis and disease progression. In the multivariate analysis, VEGF-A, IGF-I and IGF-IR were observed to be independent predictors for overall survival, whereas TGF-β1 and lymph node status were identified as independent predictors for disease-free survival. The overall response rate was significantly lower in patients with TNBC and those with high levels of TGF-β1, IGF-I/IGF-IR and VEGF-A. In view of the present results, it was concluded that TGF-β1, IGF-I/IGF-IR and VEGF-A overexpression is associated with the presence of aggressive tumors, which exhibit an increased probability of metastasis, a poor response to treatment and reduced survival rate. This indicates that VEGF-A, IGF-IR and IGF-I have the potential to be used as surrogate biomarkers and are promising candidates for targeted therapy, particularly in patients with TNBC.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results